Tesamorelin is the only FDA-approved GHRH analog, used clinically to reduce excess visceral fat in HIV patients on antiretroviral therapy, and under investigation for cognitive benefits.
What it does
Tesamorelin is a synthetic copy of the body's own growth hormone-releasing hormone (GHRH) — the signal the hypothalamus sends to the pituitary to trigger growth hormone (GH) release. It matches the full 44-amino acid GHRH sequence, with one chemical modification at the end of the chain (a trans-3-hexenoic acid group) that slows breakdown and extends its activity compared to naturally occurring GHRH.
When injected, tesamorelin binds to GHRH receptors on pituitary somatotrophs (the cells that produce and secrete GH). This activates a cAMP/PKA signaling cascade — essentially a biochemical relay that tells those cells to release GH. The resulting GH pulse then stimulates the liver to produce IGF-1 (insulin-like growth factor 1), the downstream hormone responsible for most of GH's tissue-level effects, including fat metabolism and, potentially, neuroplasticity.
What distinguishes tesamorelin from other GHRH analogs like sermorelin or CJC-1295 is regulatory status, not mechanism. It works through the same pituitary pathway but carries FDA approval — specifically for reducing visceral adipose tissue (VAT, the metabolically active fat stored around the abdominal organs) in people living with HIV.
What the evidence shows
HIV-associated lipodystrophy (visceral fat reduction) Strong — multiple Phase III randomized controlled trials, FDA-approved indication
The clearest evidence for tesamorelin is in HIV-associated lipodystrophy, a condition where antiretroviral therapy drives accumulation of visceral fat around the abdomen. Phase III double-blind, placebo-controlled trials showed 15–18% reductions in VAT with 2 mg/day subcutaneous dosing Farah 2023. A 2024 study confirmed similar efficacy in people on integrase inhibitor-based regimens — the most common modern antiretroviral class — with a favorable safety profile C 2024. Tesamorelin also shows early signals for improving metabolic markers in HIV-related liver disease, including metabolic dysfunction-associated steatotic liver disease (MASLD), a growing concern in this population K 2025.
Cognitive function and neurocognitive impairment Promising — multiple small human trials, mechanism plausible via GH/IGF-1 and hippocampal function
GH and IGF-1 support hippocampal neuroplasticity (the brain's ability to form and reorganize neural connections), which provides a plausible basis for cognitive effects. Stanley et al. 2016 showed tesamorelin improved verbal memory in patients with mild cognitive impairment. More recently, a 2025 trial examined its effects on neurocognitive impairment specifically in people with HIV and abdominal obesity, finding measurable improvements J 2025. CROI 2024 conference data also flagged tesamorelin among agents with neuropsychiatric relevance in HIV J 2024. Trials remain small — this is a real and active area of investigation, not yet a settled indication.
Dorsocervical fat (buffalo hump) reduction Moderate — post-hoc analysis of Phase III data
A post-hoc analysis of Phase III trial data found that tesamorelin reduced dorsocervical fat (the fatty deposit at the back of the neck common in HIV lipodystrophy) in addition to abdominal VAT Farah 2023. This is a secondary finding from a trial powered for VAT, not a primary endpoint, so it carries less weight — but the signal is consistent with tesamorelin's broader effect on ectopic fat depots.
Sleep-disordered breathing and cardiac steatosis Investigational — registered trials, no published results yet
Two registered trials are actively exploring tesamorelin's effects on sleep apnea NCT01788462 and cardiac steatosis (fat accumulation in heart tissue) in people with HIV NCT03826160. A third trial is assessing it as an adjunct to exercise for physical function NCT06554717. These are open questions, not established uses.
How it's used
In clinical trials and the FDA-approved label, the standard dose is 2 mg subcutaneously (injected under the skin of the abdomen) once daily. Some protocols use 1 mg/day as a lower starting dose. The half-life is short — roughly 26 to 38 minutes — so consistent daily dosing is required to maintain IGF-1 elevation. Timing within the day appears flexible; studies have not established a clear advantage to morning versus evening injection. Injection sites should be rotated within the abdomen. In studies and self-reported protocols, doses range from 1 mg to 2 mg daily, with 2 mg being the studied and approved dose for lipodystrophy.
Side effects and safety
The most commonly reported side effects in trials are injection site reactions (redness, itching, swelling), mild peripheral edema (fluid retention causing puffiness, particularly in the extremities), arthralgia (joint pain), and myalgia (muscle aches) C 2024 Farah 2023. Paresthesia (tingling or numbness, typically in hands and feet) occurs in a subset of users. Pharmacovigilance data also flag carpal tunnel syndrome as a potential adverse effect associated with GH-elevating medications in this class Andrew 2025.
Because tesamorelin raises GH and IGF-1, it can impair insulin sensitivity and raise blood glucose — people with diabetes or prediabetes should monitor glycemic markers closely. Severe adverse events are uncommon but include significant fluid retention and hypersensitivity reactions.
Absolute contraindications are active malignancy (GH/IGF-1 can promote tumor growth), disruption of the hypothalamic-pituitary axis (hypopituitarism, prior pituitary surgery or radiation), and pregnancy. Severe retinopathy is a relative contraindication. Long-term safety data beyond the trial durations used for FDA approval are limited — extended use in non-HIV populations is largely unstudied.
Bottom line
Tesamorelin has genuine, well-controlled trial evidence behind its FDA-approved use for HIV-associated lipodystrophy, and credible early data for cognitive benefits in relevant populations. Outside of HIV lipodystrophy, evidence is promising but still thin. It is the only GHRH analog available through legal, regulated channels in the US, which matters for practitioners and patients who care about that distinction.